LGND — Ligand Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.91bn
- $1.69bn
- $131.31m
- 80
- 26
- 99
- 76
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 629 | -2.98 | 57.1 | -33.4 | 52.2 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | -748 | 61 | 31.4 | 33.3 | -16.4 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -4.21 | -10.1 | -52.2 | 65.7 | -34.4 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -29.3 | 54.6 | 78.8 | 138 | 49.6 |
Capital Expenditures | -2.55 | -4.46 | -8.76 | -17.9 | -64.3 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 469 | 236 | 39.3 | 182 | 52.6 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Sale of Intangible Assets | |||||
Change in Net Intangibles | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 467 | 232 | 30.5 | 164 | -11.7 |
Financing Cash Flow Items | -7.42 | -3.81 | 11.9 | -18.2 | -5.5 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -485 | -311 | -138 | -276 | -59.9 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -47.5 | -24.3 | -28.4 | 25.5 | -22.1 |